|
Title
|
|
|
|
Characterization of duramycin as a SPECT imaging agent for early assessment of tumor apoptosis
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Purpose We investigated the usefulness of [99mTc]duramycin for monitoring early response to cancer therapy in mice, with an eye towards clinical translation. Procedures [99mTc]Duramycin was injected in healthy CD1−/− mice to estimate human [99mTc]duramycin radiation dose. [99mTc]Duramycin single-photon emission computed tomography (SPECT) imaging of apoptosis was evaluated in a mouse model of colorectal cancer treated with irinotecan and validated ex vivo using autoradiography, cleaved caspase-3, and TdT-mediated dUTP nick-end labeling (TUNEL) histology of the tumors. Results The mean effective dose was estimated to be 3.74 × 10−3 ± 3.43 × 10−4 mSv/MBq for non-purified and 3.19 × 10−3 ± 2.16 × 10−4 mSv/MBq for purified [99mTc]duramycin. [99mTc]Duramycin uptake in vivo following therapy increased significantly in apoptotic irinotecan-treated tumors (p = 0.008). Radioactivity in the tumors positively correlated with cleaved caspase-3 (r = 0.85, p < 0.001) and TUNEL (r = 0.92, p < 0.001) staining. Conclusion [99mTc]Duramycin can be used to detect early chemotherapy-induced tumor cell death, and thus, may be a prospective candidate for clinical SPECT imaging of tumor response to therapy. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Molecular imaging and biology. - Place of publication unknown
|
|
|
Publication
|
|
|
|
Place of publication unknown
:
2015
|
|
|
ISSN
|
|
|
|
1536-1632
|
|
|
DOI
|
|
|
|
10.1007/S11307-015-0852-6
|
|
|
Volume/pages
|
|
|
|
17
:6
(2015)
, p. 838-847
|
|
|
ISI
|
|
|
|
000364941700013
|
|
|
Pubmed ID
|
|
|
|
25896815
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|